Journal article
Neonatal Caffeine Treatment and Respiratory Function at 11 Years in Children under 1,251 g at Birth
Lex W Doyle, Sarath Ranganathan, Jeanie LY Cheong
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | AMER THORACIC SOC | Published : 2017
Abstract
RATIONALE: Caffeine in the newborn period shortens the duration of assisted ventilation and reduces the incidence of bronchopulmonary dysplasia, but its effects on respiratory function in later childhood are unknown. OBJECTIVES: To determine if children born with birth weight less than 1,251 g who were treated with neonatal caffeine had improved respiratory function at 11 years of age compared with children treated with placebo. METHODS: Children enrolled in the CAP (Caffeine for Apnea of Prematurity) randomized controlled trial and assessed at the Royal Women's Hospital in Melbourne at 11 years of age had expiratory flow rates measured according to the standards of the American Thoracic Soc..
View full abstractGrants
Awarded by National Health and Medical Research Council of Australia
Awarded by National Health and Medical Research Council of Australia (Centre of Clinical Research Excellence)
Awarded by National Health and Medical Research Council of Australia (Centre of Research Excellence)
Funding Acknowledgements
Supported by grants from the National Health and Medical Research Council of Australia (program grant 606789; Centre of Clinical Research Excellence 546519; Centre of Research Excellence 1060733; Early Career Fellowship 1053787 [J.L.Y.C.]) and the Victorian government's operational infrastructure support program. The funding sources had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.